Regulatory January 19, 2022Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB
Non Regulatory January 19, 2022Oasmia announces intention to change its name to Vivesto
Regulatory January 19, 2022OASMIA RESOLVES ON A FULLY SECURED RIGHTS ISSUE OF APPROXIMATELY SEK 151 MILLION
Oasmia Pharmaceutical published its Q3 2021 report on November 18, 2021, at 08.00 am CET.
The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program